A tribunal has found millionaire property mogul and cosmetic surgeon Jerry Schwartz guilty of professional misconduct, after finding he inappropriately treated himself and four family members and flouted registration conditions by administering fentanyl to patients.
AstraZeneca has sued Pharmacor over its plans to list a generic version of blockbuster diabetes drug Forxiga on the PBS, but the drug maker will have to defend the validity of the patent, which was struck down by a UK court last year.
NSW’s solicitor wellbeing service, SoWell, will now offer couples counselling, with the NSW Law Society acknowledging how the mental health challenges affecting legal professional can impact personal relationships.
Merck KGaA has failed to block Pfizer’s ‘Abrysvo’ trade mark for its RSV vaccine, with a delegate finding no likelihood of confusion with the mark for Merck’s Mavenclad MS drug despite their visual similarities.
Otsuka Pharmaceuticals has asked the High Court to overturn a decision revoking its Abilify patent extension, saying the ruling, which limited the extension-of term scheme to active substances only, will “lead to a groundswell of court proceedings”.
Class action settlements hit major milestones last year, with the year’s largest settlements totalling $1.6 billion and one case resolving for a historic $548.5 million.
A judge hearing a class action alleging Bupa failed to provide promised levels of care to residents has said she won’t put the case on ice pending the aged care provider’s potential appeal of a decision declining to toss the case.
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.
A medical assessment served under the Wrongs Act by a patient of Dr Daniel Lanzer needed to come to the attention of the surgeon himself, not just his solicitors, despite the lawyers being authorised to receive other documents in the case, an appeals court has found.
A class action against Bupa alleging the aged care provider failed to provide promised levels of care to residents can proceed, with a judge finding the case is not “fatally flawed”.